Cellectis

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Retrieved on: 
Friday, November 17, 2023
Bulletin, Aleksander Balos, CET, Euronext, Nightclub, Online shopping, ABQ BioPark Aquarium, Cellectis

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Key Points: 
  • NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
  • The notice of meeting as published today in the BALO (Bulletin des Annonces Legales Obligatoires), including the agenda, the text of the resolutions and the terms of participation, is online on the Cellectis website at the following address:

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Retrieved on: 
Wednesday, November 15, 2023
AstraZeneca, Euronext, Cellectis

Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.

Key Points: 
  • Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.
  • Extraordinary shareholders’ meeting of Cellectis to be held on or around December 22, 2023 to approve such investment.
  • NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) --  Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investment Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) regarding the contemplated additional equity investment of $140M by AstraZeneca, which was previously announced on November 1, 2023.
  • In the absence of a public offering, no prospectus will be established in France or outside of France in connection with the Additional Investment.

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

Retrieved on: 
Wednesday, November 1, 2023
Euronext Growth, Webcast, Pharmaceutical industry, Cryptocurrency, Cellectis

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 6, 2023 after the close of the US market.

Key Points: 
  • NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter ended September 30, 2023 on Monday, November 6, 2023 after the close of the US market.
  • The announcement will be followed by an investor conference call and webcast on Tuesday, November 7, 2023 at 8:00 AM ET / 2:00 PM CET.
  • The call will include the Company’s third quarter results and an update on business activities.
  • Details for the call are as follows:

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Retrieved on: 
Wednesday, November 1, 2023
Euronext, Gene editing, AstraZeneca, IND, Therapy, Rare, Alexion, Doctor of Philosophy, Research, Initial, MOU, UCART123, File, Collaboration, Investment, IP, Patient, Pharmaceutical industry, Security (finance), Cellectis

Under the terms of the Collaboration Agreement, AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products.

Key Points: 
  • Under the terms of the Collaboration Agreement, AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products.
  • As part of the Collaboration Agreement, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 candidate products could be explored for development.
  • Pursuant to the Collaboration Agreement, Cellectis’ research costs under the collaboration will be funded by AstraZeneca and Cellectis will receive an upfront payment of $25M.
  • As a condition to the signing of the Collaboration Agreement, AstraZeneca has agreed to make an initial equity investment of $80M in Cellectis by subscribing for 16,000,000 ordinary shares, at a price of $5.00 per share (the “Initial Investment”).

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Gene editing, CAR, PDT, San Diego Convention Center, Cell, SITC, Immunotherapy, Euronext Growth, Neoplasm, TGFBR2, Safety, Society, Doctor of Philosophy, Vaccine, Cellectis

The data will be presented by Laurent Poirot, Ph.D., SVP Immunology of Cellectis, in a poster session that will be held November 4th 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.

Key Points: 
  • The data will be presented by Laurent Poirot, Ph.D., SVP Immunology of Cellectis, in a poster session that will be held November 4th 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.
  • “We demonstrate that combination of the ΔPD1-IL12 with TGFBR2 KO not only enhanced CAR-T cell activity but surprisingly limit their accumulation outside the tumor, therefore reducing the risks of off-tumor toxicity.
  • These cells also show strong anti-tumor activity against distal tumors when infused intratumorally”, said Laurent Poirot, Ph.D., SVP Immunology at Cellectis.
  • These pre-clinical data highlight the capability of multi-armored allogeneic CAR T-cells to preserve their activity despite the immunosuppressive microenvironment, while mitigating potential safety concerns.

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Retrieved on: 
Thursday, October 12, 2023
PIK3CD, TALEN, Euronext Growth, Research, Mythic Imagination Institute, Vaccine, Management, Cellectis

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells.

Key Points: 
  • NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy – Methods & Clinical Development, demonstrating the efficacy of its TALEN-mediated gene correction of mutated PIK3CD gene in APDS1 T-cells.
  • The research work described in this article was jointly conducted by Imagine Institute and Cellectis teams.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Triple-negative breast cancer, Society, Euronext Growth, San Diego Convention Center, SITC, Immunotherapy, PDT, EDT, CAR, Journal, JITC, Poster, MUC1, Vaccine, Cellectis

Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.

Key Points: 
  • Laurent Poirot, SVP Immunology of Cellectis, will present a poster on the benefits of combining potency attributes for TALEN®-edited smart CAR T-cells targeting MUC1 in preclinical models of triple-negative breast cancer.
  • Title: TGF-Beta Blockade Combined with Activation-Induced IL12 Secretion Synergize to Optimize Potency of MUC1-CAR T-cells in Preclinical Targeting of Triple-Negative Breast Cancer.
  • Date/Time: Poster will be on display Saturday, November 4th, 2023 from 9:00 a.m. to 8:30 p.m. PDT, at San Diego Convention Center, Hall A.
  • Full text of the abstract will be made public on October 31, 2023 at 9:00 a.m. EDT on the SITC website and in a Journal for ImmunoTherapy of Cancer (JITC) supplement published on Oct. 31st, 2023 at 6 a.m. PDT/9 a.m. EDT.

Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

Retrieved on: 
Wednesday, July 12, 2023
Molecular biology, Euronext Growth, Therapy, OncoMed, File, Doctor of Philosophy, TIL, Biotechnology, Gene editing, Research, Cellectis, Iovance Biotherapeutics, Harvard Medical School, CAR, Sheree Toth, IND, Pharmaceutical industry

“We are very excited to welcome Dr. Chartier as a director of Cellectis’ Board of Directors.

Key Points: 
  • “We are very excited to welcome Dr. Chartier as a director of Cellectis’ Board of Directors.
  • I am keen to lend my insights to the Cellectis’ Board of Directors to serve a patient population with severe unmet medical needs, where a successful allogeneic CAR T-cell product candidate could be a major breakthrough,” said Cécile Chartier, Ph.D., Cellectis newest Board member.
  • Cécile Chartier currently serves as Chief Scientific Officer at NextVivo, Inc.
  • She also worked at Shering (US Berlex) and Transgene (France), where she focused on gene therapy.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023

Retrieved on: 
Wednesday, June 28, 2023
United Nations Security Council Resolution 29, Euronext, CET, Television, Cellectis, ABQ BioPark Aquarium

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Key Points: 
  • NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
  • At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations.
  • The detailed results of the vote and the resolutions are available on the company’s website:

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Retrieved on: 
Monday, June 5, 2023
Graft-versus-host disease, HD, Antigen, DNA, BP, TRAC, HSPC, Euronext Growth, Interferon gamma, UGI, CD19, Red blood cell, ISCT, Lymphoid leukemia, CD20, Neoplasm, Thymine, Patient derived xenograft, Survival, Gene editing, Bone marrow, CD52, CD22, Deamination, Toxicity, Cell, Stem cell, PDX, CAR, Patient, Risk, Engineering, International Society, Knowledge, HBB, TALEN, TC, Phenotype, Vaccine, Online shopping, Cosmetics, HBSS, Cellectis, Cytosine

The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.

Key Points: 
  • The therapeutic options after CAR T-cell relapses are limited, emphasizing the need to develop novel therapies to improve current survival rates.
  • UCART20x22 is Cellectis’ first dual-targeting, allogeneic cell therapy product candidate targeting CD20 and CD22, to address the current challenges in the treatment of B-cell malignancies.
  • The oral presentation highlighted the following preclinical data:
    Robust in vitro and in vivo cytolytic activity against tumors expressing different antigen combinations.
  • The oral presentation is available on Cellectis’ website: https://www.cellectis.com/en/investors/scientific-presentations/
    Sickle cell disease stems from a single point mutation in the HBB gene which results in sickle hemoglobin.